Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement component C5. Eculizumab must be administered intrav...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xuan, Gavriilaki, Eleni, Thanassi, Jane A., Yang, Guangwei, Baines, Andrea C., Podos, Steven D., Huang, Yongqing, Huang, Mingjun, Brodsky, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394948/
https://www.ncbi.nlm.nih.gov/pubmed/27810992
http://dx.doi.org/10.3324/haematol.2016.153312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394948/
https://www.ncbi.nlm.nih.gov/pubmed/27810992
http://dx.doi.org/10.3324/haematol.2016.153312

Ejemplares similares